But the KFF Employer Health Benefits Survey shows that even though employers who said they offered obesity drug coverage grew from 18% in 2024 to 19% in 2025, those that said they didn't offer it also increased from 52% to 57% over the same period
This large-scale retrospective cohort study drew on electronic health record data for 60,860 adults aged 40 years or older with both type 2 diabetes and obesity enrolled in the TriNetX US network between December 2017 and June 2024
Promotes neurological health and mental energy Supports improved learning, attention, long-term memory, and mood Improves neuropathy (nerve pain) in certain conditions May help improve the symptoms of anxiety Helps the body produce energy at the cellular level Carnitine and its derivatives exist in a carnitine pool in the body
A lower price doesnt automatically mean poor care but it does mean you should know exactly what youre paying for
Warnings Consult your doctor before use if you are pregnant, breastfeeding, or have any medical conditions
Yes, MeAgain tracks various GLP-1 medications including Ozempic, Wegovy, Mounjaro, Zepbound, semaglutide, and tirzepatide, as well as oral GLP-1s and weekly injection routines